At-home chemotherapy teaching for people with myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests whether people with symptomatic myeloma can safely learn to give themselves chemotherapy at home. It aims to make treatment easier while tracking safety and whether treatment is done correctly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and have symptomatic myeloma (multiple myeloma causing symptoms).
- Your care team feels your health is stable enough for home treatment.
- You (or a caregiver) are willing and can be taught to give the injections at home.
- You’ve already had more than 4 bortezomib injections in a hospital or cancer center.
- You must not currently be in another study that uses bortezomib, and you can sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if people with relapsed multiple myeloma can safely give themselves a medicine called elranatamab at home. It aims to make treatment more convenient while still being safe and effective.
This trial tests if people with multiple myeloma can safely give themselves a medication called daratumumab under the skin at home, instead of going to the hospital for every dose. It aims to see if home self-administration is practical and acceptable for patients.
This Phase 2 trial tests a combination of medicines (iberdomide, bortezomib, dexamethasone, and adding isatuximab) for people with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to improve disease control while checking safety in older adults who can take pills and attend frequent visits.
This study compares different combinations of medicines for people newly diagnosed with multiple myeloma who cannot safely get a stem cell transplant. It aims to find which drug plan works best and is tolerable for people with “frail” or “intermediate fit” health.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
This Phase 2 trial tests whether a combination of anti-myeloma medicines given before stem cell transplant works well and is safe for people with multiple myeloma who also have kidney problems. It may help control the myeloma and prepare you for the transplant.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.